{"id":"W4405047886","doi":"10.1182/blood-2024-194382","title":"Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Moderna; Juno Therapeutics; Incyte; BeiGene; Pharmacyclics; Genentech; MEI Pharma; TG Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; MorphoSys; Celgene; Seagen; Gilead Sciences","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Internal medicine; Medicine; Oncology; Population; Survival analysis; Leukemia; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007452677,0.0009349986,0.002761266,0.001144935,0.000219263,0.001395784,0.0004839164,0.0007444655,0.001168313],"category_scores_gemma":[0.006994396,0.0004523777,0.009531165,0.001214097,0.0002695182,0.0007589745,0.0007318733,0.0008957851,0.0001724364],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005739765,"about_ca_system_score_gemma":0.0005798679,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001050952,"about_ca_topic_score_gemma":0.002667431,"domain_scores_codex":[0.9962352,0.002221977,0.0004210256,0.0005616976,0.0003371447,0.0002230334],"domain_scores_gemma":[0.9961354,0.00154451,0.001335308,0.0005043319,0.0002588647,0.0002216232],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.2044878,0.0006985001,0.308001,0.003344249,0.3670233,0.0002579949,0.0002329952,0.004280171,0.004921379,0.000115638,0.002810897,0.1038261],"study_design_scores_gemma":[0.02594311,0.02366965,0.7023917,0.0005044666,0.2357661,0.0006693404,0.0001930968,0.003867889,0.001747443,0.0004643911,0.004667084,0.0001155961],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9214627,0.07322706,0.001521282,0.0002995063,0.000150729,0.0002662117,0.002010991,0.00009077789,0.0009708031],"genre_scores_gemma":[0.9936347,0.00372203,0.0004105164,0.000268811,0.00009686529,0.0001247517,0.001522094,0.00001386418,0.0002063346],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007452677,"threshold_uncertainty_score":0.03941405,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01788982418829464,"score_gpt":0.3004515958929991,"score_spread":0.2825617717047044,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}